Effect of the 5-HT1 agonist sumatriptan on oesophageal motor pattern in patients with ineffective oesophageal motility

Neurogastroenterology and Motility

Volumn 15, Issue 1, 2003, Pages 9-14

  Grossi, Laurino ^a   Ciccaglione, A F ^a   Marzio, L ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

5 HT; Ineffective oesophageal motility; Manometry; Oesophageal motility; Sumatriptan

Indexed keywords

PLACEBO; SEROTONIN 1 AGONIST; SUMATRIPTAN; SEROTONIN AGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPHAGIA; ENDOSCOPY; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS MOTILITY; FEMALE; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; MANOMETRY; PERISTALSIS; PRIORITY JOURNAL; SWALLOWING; DRUG EFFECT; ESOPHAGUS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; DEGLUTITION; ESOPHAGEAL MOTILITY DISORDERS; ESOPHAGUS; FEMALE; HUMANS; MALE; MANOMETRY; MIDDLE AGED; PERISTALSIS; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0037295214     PISSN: 13501925     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2982.2003.00380.x     Document Type: Article

References (25)

1. Brown EG, Endersby CA, Smith RN et al. The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991; 31: 339-44.
2. Castle WM, Simmons VE. Coronary vasospasm and sumatriptan. Br Med J 1992; 305: 117-8.
3. Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. Headache 1996; 36: 329-31.
4. Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet 1994; 344: 985-6.
5. 1 agonist, sumatriptan. Aliment Pharmacol Ther 1999; 13: 927-36.
6. 1 agonist, on the frequency of transient lower esophaeal sphincter relaxations and gastroesophageal reflux in healthy subjects. Am J Gastroenterol 1999; 94: 3158-64.
7. Leite LP, Johnston BT, Barrett J et al. Ineffective esophageal motility (IEM). The primary finding in patients with non specific esophageal motility disorders. Dig Dis Sci 1997; 42: 1859-65.
8. Anggiansah A, Taylor G, Bright N et al. Primary peristalsis is the major acid clearance mechanism in reflux patients. Gut 1994; 35: 1536-42.
9. Fouad YM, Katz PO, Hatlebakk JG, Castell DO. Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms. Am J Gastroenterol 1999; 94: 1464-7.
10. Pimentel M, Bonorris GG, Chow EJ, Lin HC. Peppermint oil improves the manometric findings in diffuse esophageal spasm. J Clin Gastroenterol 2001; 33: 27-31.
11. 1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am J Physiol 1997; 272: G902-8.
12. 1-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther 1992; 6: 685-91.
13. Tack J, Coulie B, Wilmer A, Andrioli A, Janssens J. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000; 46: 468-73.
14. Mittal RK, Holloway RH, Penagini R et al. Transient lower esophageal sphincter relaxation. Gastroenterology 1995; 109: 601-10.
15. McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastro-esophageal reflux. Gastroenterology 1981; 80: 285-91.
16. Bremner RM, Hoeft SF, Costantini M, Crookes PF, Bremner CG, DEMeester TR. Pharyngeal swallowing. The major factor in clearance of esophageal reflux episodes. Ann Surg 1993; 218: 364-9.
17. Foster JM, Houghton LA, Whorwell PJ. Further evidence that sumatriptan induced chest pain is esophageal in origin: effect on esophageal visceral sensation. Gastroenterology 1997; 112: 563 A (abstract).
18. Holloway RH, Kocyan P, Dent J. Provocation of transient lower esophageal sphincter relaxations by meals in patients with symptomatic gastroesophageal reflux. Dig Dis Sci 1991; 36: 1043-9.
19. Tack J, Coulie B, Wilmer A, Peeters T, Janssens J. Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptan on interdigestive gastrointestinal motility in man. Gut 1998; 42: 36-41.
20. Marzio L, Grossi L, Falcucci M, Ciccaglione AF, Malatesta MG, Lapenna D. Increase of swallows before onset of phase III of migrating motor complex in normal human subjects. Dig Dis Sci 1996; 41: 522-7.
21. 1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology 1997; 36: 535-42.
22. Sleight AJ, Cervenka A, Peroutka SJ. In vivo effects of sumatriptan (GR43175) on extracellular levels of 5-HT in the guinea-pig. Neuropharmacology 1990; 29: 511-13.
23. 3 receptors are involved in the initiation of gastric phase 3 motor activity in man. Gastroenterology 1993; 105: 773-8.
24. Chester AH, O'Neil GS, Yaccoub MH. Sumatriptan and ischaemic heart disease. Lancet 1993; 341: 1419-20.
25. Yamato S, Spechler SJ, Goyal RK. Role of nitric oxide in esophageal peristalsis in the opossum. Gastroenterology 1992; 103: 197-204.